rs10903343
This variant is located in the FDFT1 gene.
▶GWAS Catalog Trait Associations (26)
Genome-wide significant associations (p < 5×10⁻⁸) from the NHGRI-EBI GWAS Catalog.
GWAS Catalog Trait Associations (26)
Genome-wide significant associations (p < 5×10⁻⁸) from the NHGRI-EBI GWAS Catalog.
low density lipoprotein cholesterol measurement, phospholipids:total lipids ratio
Richardson TG et al. “Characterising metabolomic signatures of lipid-modifying therapies through drug target mendelian randomisation.” Plos Biology 20(2):e3001547 (2022)
Allele T
OR 0.04
p 2.0e-26
N 115,082
Large GWAS
European
low density lipoprotein cholesterol measurement, cholesteryl esters:total lipids ratio
Richardson TG et al. “Characterising metabolomic signatures of lipid-modifying therapies through drug target mendelian randomisation.” Plos Biology 20(2):e3001547 (2022)
Allele T
OR 0.04
p 3.0e-26
N 115,082
Large GWAS
European
free cholesterol measurement, blood VLDL cholesterol amount, chylomicron amount
Richardson TG et al. “Characterising metabolomic signatures of lipid-modifying therapies through drug target mendelian randomisation.” Plos Biology 20(2):e3001547 (2022)
Allele T
OR 0.04
p 1.0e-22
N 115,082
Large GWAS
European
total cholesterol measurement, blood VLDL cholesterol amount, chylomicron amount
Richardson TG et al. “Characterising metabolomic signatures of lipid-modifying therapies through drug target mendelian randomisation.” Plos Biology 20(2):e3001547 (2022)
Allele T
OR 0.04
p 1.0e-21
N 115,082
Large GWAS
European
triglyceride measurement, blood VLDL cholesterol amount
Richardson TG et al. “Characterising metabolomic signatures of lipid-modifying therapies through drug target mendelian randomisation.” Plos Biology 20(2):e3001547 (2022)
Allele T
OR 0.04
p 2.0e-21
N 115,082
Large GWAS
European
phospholipid level, blood VLDL cholesterol amount, chylomicron amount
Richardson TG et al. “Characterising metabolomic signatures of lipid-modifying therapies through drug target mendelian randomisation.” Plos Biology 20(2):e3001547 (2022)
Allele T
OR 0.04
p 3.0e-21
N 115,082
Large GWAS
European
low density lipoprotein cholesterol measurement, free cholesterol:total lipids ratio
Richardson TG et al. “Characterising metabolomic signatures of lipid-modifying therapies through drug target mendelian randomisation.” Plos Biology 20(2):e3001547 (2022)
Allele T
OR 0.04
p 6.0e-21
N 115,082
Large GWAS
European
lipid measurement, blood VLDL cholesterol amount, chylomicron amount
Richardson TG et al. “Characterising metabolomic signatures of lipid-modifying therapies through drug target mendelian randomisation.” Plos Biology 20(2):e3001547 (2022)
Allele T
OR 0.04
p 1.0e-20
N 115,082
Large GWAS
European
cholesteryl ester measurement, blood VLDL cholesterol amount, chylomicron amount
Richardson TG et al. “Characterising metabolomic signatures of lipid-modifying therapies through drug target mendelian randomisation.” Plos Biology 20(2):e3001547 (2022)
Allele T
OR 0.04
p 2.0e-20
N 115,082
Large GWAS
European
triglyceride measurement, blood VLDL cholesterol amount, chylomicron amount
Richardson TG et al. “Characterising metabolomic signatures of lipid-modifying therapies through drug target mendelian randomisation.” Plos Biology 20(2):e3001547 (2022)
Allele T
OR 0.04
p 3.0e-19
N 115,082
Large GWAS
European
▶ClinVar annotation
About FDFT1
This gene encodes a membrane-associated enzyme located at a branch point in the mevalonate pathway. The encoded protein is the first specific enzyme in cholesterol biosynthesis, catalyzing the dimerization of two molecules of farnesyl diphosphate in a two-step reaction to form squalene. [provided by RefSeq, Jul 2008]
View all FDFT1 variants →Gene information from NCBI Gene. Variant classifications from ClinVar.
Community Wiki
No community notes yet for this variant. Sign in to start one.
Comments
Sign in to join the discussion.
Loading comments…